Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQD3606
- Development stage
- Phase 1
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**TQD3606** is an investigational intravenous fixed-dose antibacterial combination of **meropenem** and **avibactam** being developed by Chia Tai Tianqing Pharmaceutical Group. Meropenem is a broad-spectrum carbapenem that inhibits bacterial penicillin-binding proteins and cell-wall synthesis, while avibactam is a reversible covalent inhibitor of susceptible serine beta-lactamases that protects meropenem from enzymatic degradation. The combination is in Phase 1 clinical development in China, including pharmacokinetic, safety, urinary-excretion, and renal-impairment studies for bacterial infections, including carbapenem-resistant bacterial infections.
- Other names
- meropenem + avibactamTQD-3606TQD3606TQD 3606
02
Targets
PBP (Penicillin-binding protein family)Neuraminidase
Beyond the preview
Go deeper on TQD3606.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQD3606.